Anne Fleur Kortekaas-Rijlaarsdam

61 MPH EFFECTS ON MATH PERFORMANCE: INFLUENCE OF BEHAVIOR 3 Medication Design A randomized double-blind placebo-controlled crossover design was used in which children with ADHD received both extended release methylphenidate (Equasym XL®, Shire Pharmaceuticals, Amsterdam, The Netherlands) and placebo for seven subsequent days. Equasym XL® has an eight hour duration of action with a 30% component of immediate release and a 70% component of extended-release 4-5 hours after dosing (Banaschewski et al., 2006). All children were treated with stable doses of methylphenidate (mean duration of treatment was 30.7 months, SD = 19.1). Before enrollment in the study, medication washout was achieved using a period of at least 48 hours prior to the start of the first treatment week and between the two treatment weeks. Children were tested on the last day of each treatment week at their own primary school. Medication was prescribed by the treating physician. Doses were identical to Figure 3.1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participants during enrollment, allocation and analysis